Adherence to antipsychotic drug treatment in early-episode schizophrenia: A six-month naturalistic follow-up study

2011 ◽  
Vol 130 (1-3) ◽  
pp. 176-181 ◽  
Author(s):  
Vered Baloush-Kleinman ◽  
Stephen Z. Levine ◽  
David Roe ◽  
Dan Shnitt ◽  
Abraham Weizman ◽  
...  
Keyword(s):  
Drug Treatment ◽  
Antipsychotic Drug ◽  
Follow Up Study ◽  
Antipsychotic Drug Treatment

scholarly journals M41. TRAJECTORIES AND PREDICTORS OF OUTCOME IN SCHIZOPHRENIA: THE BENEFICIAL ROLE OF AMISULPRIDE

2020 ◽  
Vol 46 (Supplement_1) ◽  
pp. S149-S150
Author(s):  
Petros Drosos ◽  
Erik Johnsen ◽  
Christoffer A Bartz-Johannessen ◽  
Rune A Kroken
Keyword(s):  
Drug Treatment ◽  
Antipsychotic Drug ◽  
Antipsychotic Drugs ◽  
Strong Response ◽  
Schizophrenia Spectrum ◽  
Significant Difference ◽  
One Year ◽  
Response Group ◽  
Antipsychotic Drug Treatment

Abstract Background Schizophrenia is a serious illness and treatment with antipsychotic drugs remains one of the most effective types of treatment. The course of schizophrenia, however, is highly heterogeneous and currently it is not possible to predict which patient will respond adequately to which antipsychotic drug. The aim of our study was to define trajectories regarding response to antipsychotic drug treatment in patients with schizophrenia spectrum disorders. A second aim was to evaluate demographic factors and antipsychotic drugs as predictors for the different trajectories. Methods Best Intro is a randomized, rater-blind, head-to-head comparison of amisulpride, aripiprazole and olanzapine. Adult patients with a diagnosis in the schizophrenia spectrum (ICD-10 diagnoses F20-29) were included. Participants had symptoms of ongoing psychosis as determined by a score of four or more on at least one of the following PANSS (Positive and Negative Syndrome Scale) items: P1 (delusions), P3 (hallucinations), P5 (grandiosity), P6 (suspiciousness/persecution) or G9 (unusual thought content). Patients were followed over a period of 52 weeks and the assessment points were at baseline, after one week, three weeks, six weeks, three months, six months, nine months, and 12 months. Totally 359 patients were assessed for eligibility, and 144 of them were enrolled and randomized to one of the study drugs. We used the R statistical program to define trajectories of antipsychotic response. Results We identified three different trajectories regarding the reduction of PANSS total score, with Bayesian information criterion (BIC) = 6157 (BIC for two groups=6164 and for four groups=6171). A large group of patients (N=106, 74%) showed a trajectory of good improvement in PANSS total score over the first 26 weeks of follow-up and maintained it after one year with a total of 35% reduction in PANSS total score (Good response group). A second group of patients (N=19, 13%) followed a trajectory of quick response (already at one week) and a large reduction of PANSS total score (Strong response group). After one year, the reduction of PANSS total score was 58%. There was a difference in the starting point for PANSS total score in these two groups with a higher value at baseline in the Strong response group, but the ending point was quite similar. A third group of patients (N= 19, 13%) followed a trajectory of poor improvement and a 9% reduction in PANSS total score over the studied period (Slight response group). The demographic variables age, sex, civil status and living alone, or drug naivety did not predict participants grouping in the various trajectories. Furthermore, we examined the predictive value of different antipsychotic drug treatment for the different trajectories with the “Intention to treat” method. There was a statistically significant difference in favor of amisulpride treatment for belonging to the Strong response group, while olanzapine strongly predicted the belonging to the Slight response group. There was no significant difference among the antipsychotic drugs regarding the Good response group. Discussion Most patients (74%) with a schizophrenia spectrum diagnosis showed a good response during the one year follow-up and another 13% showed a remarkable strong improvement. That means that a total of 87% of patients had a satisfactory course of illness during the first year. Use of amisulpride predicts a better course compared to aripiprazole and olanzapine. This finding can be useful for clinicians when selecting antipsychotic drugs for their patients.

II. the Incidence of Compliance Problems, Side-effects, Neurotic Symptoms and Depression

1985 ◽  
Vol 146 (5) ◽  
pp. 469-474 ◽  
Keyword(s):  
Side Effects ◽  
Drug Treatment ◽  
Tardive Dyskinesia ◽  
Antipsychotic Drug ◽  
Psychotic Symptoms ◽  
Acute Psychosis ◽  
Patient Admissions ◽  
Depot Neuroleptics ◽  
Antipsychotic Drug Treatment

SummarySeven years after the completion of the original trial, over 73% of patients were maintained on depot neuroleptics, and 70% had received such medication for over seven years. About 40% had presented with a problem of compliance at some time, and there was a significant correlation between poor compliance and in-patient admissions and schizophrenic relapses. The prevalence of parkinsonian side-effects, akathisia, and tardive dyskinesia was low. Non-psychotic symptoms were common, even in the absence of acute psychosis. Depression was found in a subgroup of patients; it was frequently reported as an indication for admission during follow-up period, and seemed to be part of the schizophrenic illness rather than a result of antipsychotic drug treatment.

Post-Mortem Antipsychotic Drug Concentrations and Unexplained Deaths

1994 ◽  
Vol 165 (6) ◽  
pp. 787-791 ◽  
Author(s):  
Nedzara Jusic ◽  
Malcolm Lader
Keyword(s):  
Drug Treatment ◽  
Antipsychotic Drug ◽  
Drug Regimen ◽  
The Body ◽  
Electrolyte Balance ◽  
Post Mortem ◽  
Unexpected Death ◽  
Legal Cases ◽  
Drug Concentrations ◽  
Antipsychotic Drug Treatment

BackgroundThe relationship between antipsychotic drug treatment and sudden unexplained death remains unclear. The estimation of post-mortem blood drug concentrations should be helpful.MethodEight medico-legal cases were reviewed with respect to behaviour of patient, type and dosage of drug treatment, mode of death, post-mortem findings and drug concentrations.ResultsThe problems of evaluating such drug levels are discussed. Five of the eight patients had probably toxic concentrations of antipsychotic and/or antidepressants, which caused death, usually involving cardiac arrhythmias.ConclusionsIn cases of sudden unexpected death, a sample of blood from a peripheral vein should be obtained immediately death is pronounced or the body discovered, and sent for analysis. To minimise such fatalities, the patient should be monitored carefully, with ECG if feasible, and electrolyte balance checked. The drug regimen used should be kept simple and large doses of antipsychotics and/or antidepressants avoided wherever possible.

scholarly journals Risk of diabetes and dyslipidemia during clozapine and other antipsychotic drug treatment of schizophrenia in Iceland

2017 ◽  
Vol 71 (7) ◽  
pp. 496-502 ◽  
Author(s):  
Oddur Ingimarsson ◽  
James H. MacCabe ◽  
Magnús Haraldsson ◽  
Halldóra Jónsdóttir ◽  
Engilbert Sigurdsson
Keyword(s):  
Drug Treatment ◽  
Antipsychotic Drug ◽  
Antipsychotic Drug Treatment

Compliance with antipsychotic drug treatment: influence of side effects

1994 ◽  
Vol 89 (s382) ◽  
pp. 11-15 ◽  
Author(s):  
Fleischhacker WW ◽  
Meise U ◽  
Günther V ◽  
Kurz M
Keyword(s):  
Side Effects ◽  
Drug Treatment ◽  
Antipsychotic Drug ◽  
Antipsychotic Drug Treatment

Ontogeny of the effect of antipsychotic drug treatment on neurotensin concentrations in the rat brain

Synapse ◽  
1995 ◽  
Vol 20 (3) ◽  
pp. 244-248 ◽  
Author(s):  
Becky Kinkead ◽  
Michael J. Owens ◽  
Charles B. Nemeroff
Keyword(s):  
Drug Treatment ◽  
Rat Brain ◽  
Antipsychotic Drug ◽  
Antipsychotic Drug Treatment
Sign in / Sign up

Export Citation Format

Share Document